Management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS trial

We read the results of the Neo-AEGIS trial with great interest.1 Reynolds JV Preston SR O'Neill B et al. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023; 8: 1015-1027 Summary Full Text Full Text PDF PubMed Scopus (3) Google Scholar Over the past two decades, multimodality treatment combining chemotherapy or chemoradiotherapy with surgery has become standard treatment for resectable oesophageal cancer. 2 Cunningham D Allum WH Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355: 11-20 Crossref PubMed Scopus (5068) Google Scholar , 3 van Hagen P Hulshof MCCM van Lanschot JJB et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366: 2074-2084 Crossref PubMed Scopus (4000) Google Scholar The current clinical need is to discern the preferable option for specific groups of patients. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trialAlthough underpowered and incomplete, Neo-AEGIS provides the largest comprehensive randomised dataset for patients with adenocarcinoma of the oesophagus and oesophagogastric junction treated with perioperative chemotherapy (predominantly the modified MAGIC regimen), and CROSS trimodality therapy, and reports similar 3-year survival and no major differences in operative and health-related quality of life outcomes. We suggest that these data support continued clinical equipoise. Full-Text PDF Open AccessManagement of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS trial – Authors' replyWe thank Sri Siravajan, Teus J Weijs, Kadriye Bir Yücel, and their colleagues for their interest in our Neo-AEGIS trial.1 Full-Text PDF